Literature DB >> 30282317

Copper radiopharmaceuticals for theranostic applications.

Anife Ahmedova1, Boyan Todorov2, Nikola Burdzhiev2, Christine Goze3.   

Abstract

The growing advancement in nuclear medicine challenges researchers from several different fields to integrate imaging and therapeutic modalities in a theranostic radiopharmaceutical, which can be defined as a molecular entity with readily replaceable radioisotope to provide easy switch between diagnostic and therapeutic applications for efficient and patient-friendly treatment of diseases. For such a reason, the diagnostic and therapeutic potential of all five medical radionuclides of copper have thoroughly been investigated as they boost the hope for development of successful radiotheranostics. To facilitate the mutual understanding between all different specialists working on this multidisciplinary field, we summarized the recent updates in copper-based nuclear medicine, with specific attention to the potential theranostic applications. Thereby, this review paper is focused on the current achievements in the copper-related complementary fields, such as synthetic and nuclear chemistry, biological assessment of radiopharmaceuticals, design and development of nanomaterials for multimodal theranostic implications. This work includes: i) description of available copper radionuclide production methods; ii) analyses of the synthetic strategies for development of improved copper radiopharmaceuticals; iii) summary of reported clinical data and recent preclinical studies from the last five years on biological applicability of copper radiopharmaceuticals; and iv) illustration of some sophisticated multimodal nanotheranostic agents that comprise several imaging and therapeutic modalities. Significant advancement can be seen in the synthetic procedures, which enables the broader implication of pretargeting approaches via bioorthogonal click reactions, as well as in the nanotechnology methods for biomimetic construction of biocompatible multimodal copper theranostics. All this gives the hope that personalized treatment of various diseases can be achieved by copper theranostics in the near future.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Copper chelators; Copper radionuclides; Radioimaging; Radiopharmaceuticals; Radiotherapy; Theranostics

Mesh:

Substances:

Year:  2018        PMID: 30282317     DOI: 10.1016/j.ejmech.2018.08.051

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  11 in total

Review 1.  Radiolabeled nanomaterials for biomedical applications: radiopharmacy in the era of nanotechnology.

Authors:  Martha Sahylí Ortega Pijeira; Herlys Viltres; Jan Kozempel; Michal Sakmár; Martin Vlk; Derya İlem-Özdemir; Meliha Ekinci; Seshasai Srinivasan; Amin Reza Rajabzadeh; Eduardo Ricci-Junior; Luciana Magalhães Rebelo Alencar; Mohammed Al Qahtani; Ralph Santos-Oliveira
Journal:  EJNMMI Radiopharm Chem       Date:  2022-04-25

Review 2.  Porphyrins as Chelating Agents for Molecular Imaging in Nuclear Medicine.

Authors:  Krystyna Pyrzynska; Krzysztof Kilian; Mateusz Pęgier
Journal:  Molecules       Date:  2022-05-21       Impact factor: 4.927

3.  Preclinical PET imaging study of lung cancer with 64CuCl2.

Authors:  Qiang Wang; Dongli Song; Xiaowei Ma; Xiaodong Wu; Lei Jiang
Journal:  Ann Nucl Med       Date:  2020-06-21       Impact factor: 2.668

Review 4.  Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges.

Authors:  Julie Refardt; Johannes Hofland; Antwi Kwadwo; Guillaume P Nicolas; Christof Rottenburger; Melpomeni Fani; Damian Wild; Emanuel Christ
Journal:  Rev Endocr Metab Disord       Date:  2021-09       Impact factor: 9.306

Review 5.  Nanoscale zerovalent copper (nZVC) catalyzed environmental remediation of organic and inorganic contaminants: A review.

Authors:  Sandeep Kumar; Parminder Kaur; Ravinderdeep Singh Brar; J Nagendra Babu
Journal:  Heliyon       Date:  2022-08-08

6.  A feasibility study of the therapeutic application of a mixture of 67/64 Cu radioisotopes produced by cyclotrons with proton irradiation.

Authors:  Laura De Nardo; Gaia Pupillo; Liliana Mou; Juan Esposito; Antonio Rosato; Laura Meléndez-Alafort
Journal:  Med Phys       Date:  2022-02-20       Impact factor: 4.506

7.  Radio-enhancement effects by radiolabeled nanoparticles.

Authors:  Yaser Hadi Gholami; Richard Maschmeyer; Zdenka Kuncic
Journal:  Sci Rep       Date:  2019-10-04       Impact factor: 4.379

8.  Versatile Bispidine-Based Bifunctional Chelators for 64 CuII -Labelling of Biomolecules.

Authors:  Garima Singh; Kristof Zarschler; Sebastian Hunoldt; Irma Ivette Santana Martínez; Carmen L Ruehl; Madlen Matterna; Ralf Bergmann; Domokos Máthé; Nikolett Hegedüs; Michael Bachmann; Peter Comba; Holger Stephan
Journal:  Chemistry       Date:  2020-01-09       Impact factor: 5.236

9.  Proof-of-Concept Study of the NOTI Chelating Platform: Preclinical Evaluation of 64Cu-Labeled Mono- and Trimeric c(RGDfK) Conjugates.

Authors:  Sebastian Martin; Stephan Maus; Tobias Stemler; Florian Rosar; Fadi Khreish; Jason P Holland; Samer Ezziddin; Mark D Bartholomä
Journal:  Mol Imaging Biol       Date:  2020-08-27       Impact factor: 3.488

Review 10.  A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma.

Authors:  Julie Bolcaen; Janke Kleynhans; Shankari Nair; Jeroen Verhoeven; Ingeborg Goethals; Mike Sathekge; Charlot Vandevoorde; Thomas Ebenhan
Journal:  Theranostics       Date:  2021-07-06       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.